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Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid 
tumors showing high response rates and long durability. In melanoma, the combination 
of ipilimumab with nivolumab showed high efficacy. However, still half the patients do 
not respond to this treatment. In order to increase the therapeutic ratio in melanoma and 
other cancers, different approaches are under evaluation. Three relevant questions are at 
the moment driving the research community: how to maximize benefit while minimizing 
toxicity; how to better identify patients who are more likely to benefit from immunotherapy; 
how to convert nonresponders into responders. In this review we summarize the most recent 
findings and we outline the most likely future challenges.
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In 2016, cancer immunotherapy was named ‘Advance of the Year’ by the American Society of 
Clinical Oncology, and it has in fact emerged as a breakthrough treatment for cancers like mela-
noma, known to be resistant to classic therapeutic approaches such as chemotherapy. A number of 
cytokines, including IL-2, IFN-α and IL-12, and vaccines have been tried with various degrees of 
success with a survival benefit being observed in a very small fraction of patients [1]. Anti-CTLA-4 
and anti-PD1 antibodies have extended the survival benefit to a much larger number of patients, 
making the checkpoint blockades the most successful drugs of the past few years.
Of all cancer types, melanoma has been the most investigated. More immunotherapy drugs are 
indeed approved for melanoma than for any other type of cancer and more are in development. 
Melanoma has always shown higher responsiveness to immunotherapeutic approaches compared 
with the other solid tumors but, despite the recent very significant improvements, more than half 
the patients still do not respond to treatment. In order to increase efficacy of the immunotherapy 
in melanoma and other cancers, different approaches are under evaluation. There is a rationale and, 
therefore, a potential role for combination treatments of immunotherapy with chemotherapy, radio-
therapy or further immunotherapy. But the increased potential benefit of a combination treatment 
may come at a price of a less favorable toxicity profile. Two relevant questions are at the moment 
driving the research of the clinical and scientific community focused on immunotherapeutic treat-
ment strategies: how to maximize benefit while minimizing toxicity; how to better identify patients 
who are more likely to benefit from immunotherapy; how to convert nonresponders into responders.
Checkpoint blockades: state of art
Ipilimumab is a fully humanized anti-CTLA-4 antibody, which enables cytotoxic T-cell activity and 
perpetuates immune responses by blocking the CTLA-4 receptor. Ipilimumab was the first drug 
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to show a survival advantage in metastatic mela-
noma [2,3]. Despite the low rate of response, a 
recent pooled analysis showed that around 20% 
could be considered long-term survivors, being 
alive at 5 years after treatment [4].
Anti-PD1 and anti-PDL1 antibodies have 
more recently emerged as breakthrough drugs 
for melanoma, showing high response rates and 
long durability. In the CheckMate 066 study [5] 
comparing the anti-PD1 antibody nivolumab 
with dacarbazine in patients with BRAF wild-
type, unresectable, advanced or metastatic mela-
noma previously untreated, an overall response 
rate (ORR) of 40% was observed for nivolumab 
compared with 14% for dacarbazine. Overall 
survival (OS) was significantly increased in those 
treated with nivolumab (1 year survival rate 73 
vs 42%) and progression-free survival (PFS) 
was also increased with nivolumab (median 5.1 
vs 2.2 months). Similar results were observed 
in the CheckMate 037 Phase III trial [6] in 
405 patients previously treated with ipilimumab 
who were randomly assigned in a 2:1 ratio to 
either nivolumab or chemotherapy (ORR 38 vs 
10% respectively). Patients on nivolumab had 
a longer median duration of response (median 
not reached vs 3.5 months for chemotherapy 
treated patients). In the large CheckMate 
067 [7], 945 previously untreated patients with 
unresectable stage III or IV melanoma were ran-
domized in a 1:1:1 ratio to nivolumab alone, 
nivolumab plus ipilimumab or ipilimumab 
alone. The median PFS with both the combina-
tion and nivolumab alone was superior to ipili-
mumab alone (11.5 vs 2.9 months and 6.9 vs 
2.9 months) with an ORR for the combination, 
nivolumab alone and ipilimumab alone of 58, 
44 and 19%, respectively. OS data have been 
recently presented at the American Association 
for Cancer Research (AACR) 2017 meeting. The 
2-year OS rate was 64% for patients randomly 
assigned to nivolumab plus ipilimumab and 59 
and 45% for patients treated with single agent 
nivolumab or ipilimumab, respectively. The 
combination showed a decrease in the risk of 
death of the 12% compared with single agent 
nivolumab (descriptive analysis) [8].
The anti-PD1 antibody pembrolizumab was 
granted approval for the treatment of patients 
with metastatic melanoma based on the results 
of a very large Phase I study (KEYNOTE-001). 
In the pooled analysis of 655 patients with mela-
noma, an ORR of 34% was observed with a 
6% complete response rate. Median PFS was 5.2 
months with an OS rate at 2 years of 50% [9]. 
In the KEYNOTE-006, 834 patients with 
advanced melanoma were randomized to receive 
pembrolizumab 10 mg/kg every 2 or 3 weeks ver-
sus ipilimumab. The response rate was improved 
with pembrolizumab every 2 weeks (33.7%) 
and every 3 weeks (32.9%), as compared with 
ipilimumab (11.9%). PFS rate at 6 months 
was significantly higher for patients receiving 
pembrolizumab (47.3% for pembrolizumab 
every 2 weeks and 46.4% for pembrolizumab 
every 3 weeks) in comparison with ipilimumab 
(26.5%). Similarly, OS was improved with an 
estimated OS rate at 12 months of 74.1, 68.4 
and 58.2% for pembrolizumab every 2 weeks, 
pembrolizumab every 3 weeks and ipilimumab, 
respectively [10].
In March 2015, nivolumab received accel-
erated approval by the US FDA as second-
line treatment for metastatic non-small-cell 
lung cancer (NSCLC) of squamous histology 
that has progressed on or after platinum-con-
taining chemotherapy, based on the results of 
the CheckMate 017 study [11]. In the study, 
nivolumab showed a statistically significant pro-
longation of the median OS by 3.2 months (9.2 
vs 6.0 months) compared with single agent doc-
etaxel, with a relative 41% reduction in the risk 
of death. Median PFS (3.5 vs 2.8 months), ORR 
(20 vs 9%; p = 0.008) and 1-year OS rate (42 vs 
24%) were also superior in the nivolumab arm. 
In October of the same year, the FDA expanded 
the indication for nivolumab to include patients 
with nonsquamous NSCLC. Approval was 
based on demonstration of an improvement in 
OS as shown in the CheckMate 057 study [12]. 
In this multicenter, open-label, randomized trial 
patients with metastatic nonsquamous NSCLC 
with progression on or after platinum-based 
chemotherapy were randomized 1:1 to receive 
nivolumab or docetaxel. Nivolumab demon-
strated improved OS compared with docetaxel, 
with a median OS of 12.2 versus 9.4 months. 
The median duration of response was 17 months 
in the nivolumab arm and only 6 months in the 
docetaxel arm.
The other anti-PD1 antibody, pembroli-
zumab, was granted FDA-accelerated approval 
to treat patients with advanced NSCLC whose 
disease has progressed after other treatments 
and with tumors that express PD-L1 (tumor 
proportion score >1%). Approval was based 
on the results from the NSCLC cohorts of the 
large Phase I trial KEYNOTE-001 [13]. In the 
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overall population of 495 patients with advanced 
NSCLC, the ORR, PFS and OS were 19.4%, 
3.7 and 12 months, respectively. Patients with 
a PD-L1 score higher than 50% showed signifi-
cantly greater benefit. Results have been recently 
confirmed and extended to first-line setting by 
the KEYNOTE-024 trial [14]. In this Phase III 
study, 305 patients with previously untreated 
NSCLC and a PD-L1 expression on at least 50% 
of tumor cells were randomized to receive either 
pembrolizumab or the investigator’s choice of 
platinum-based chemotherapy. Median PFS was 
10.3 month in the pembrolizumab group with 
a median duration of response not reached ver-
sus 6.0 months in the chemotherapy group with 
a median duration of response of 6.3 months. 
Pembrolizumab approval was consequently 
extended to first-line setting for patients with a 
tumor proportion score >50%.
Atezolizumab was the first ever anti-PD-L1 
antibody approved by FDA. It is indicated for 
patients with metastatic NSCLC whose dis-
ease progressed during or following platinum-
containing chemotherapy and for patients with 
urothelial carcinoma. Approval for lung cancer 
was based on the results of a Phase III study, 
which showed improved OS and PFS for patients 
with NSCLC previously treated with atezoli-
zumab in comparison to docetaxel (median OS 
of 13.8 vs 9.6 months) [15]. Atezolizumab showed 
efficacy also in patients with urothelial carci-
noma previously treated with a platinum-based 
regimen. The reported ORR was 16% for all the 
patients and 28% for those with PD-L1 expres-
sion >5% [16]. Results are in keeping with the 
ORR observed in early phase studies with the 
PD-1 antibodies nivolumab [17] and pembroli-
zumab [18]. More recently, the other anti-PD-L1 
antibody durvalumab has granted priority review 
status by the FDA for the treatment of patients 
with locally advanced or metastatic urothelial 
carcinoma whose disease has progressed dur-
ing or after one standard platinum-based regi-
men based on the results of a Phase I/II study. 
Sixty-one patients were treated with durvalumab 
10 mg/kg every 2 weeks. The ORR was 31% in 
the 42 evaluable patients with responses ongoing 
in 12 of the 13 responding patients at a median 
follow-up of 6.5 months. ORR increased up to 
46.4% in PD-L1-positive patients [19].
Significant efficacy and prolongation of PFS 
and OS have also been observed for nivolumab 
in patients with metastatic renal cancer, clas-
sic Hodgkin lymphoma and advanced head and 
neck cancer. In patients with metastatic renal 
cancer pretreated with antiangiogenic therapy, 
nivolumab showed superiority compared with 
everolimus in terms of OS (25.0 vs 19.6 months) 
and ORR (25 vs 5%) [20]. Higher ORR and pro-
longed OS were also observed in the difficult set-
ting of patients with recurrent squamous cell car-
cinoma of the head and neck (SCCHN) whose 
disease had progressed within 6 months after 
platinum-based chemotherapy. Patients were 
randomized to receive nivolumab versus stand-
ard single-agent systemic therapy (methotrex-
ate, docetaxel or cetuximab). The median OS 
was 7.5 months in the nivolumab group versus 
5.1 months in the group that received standard 
therapy and the ORR 13.3 and 5.8%, respec-
tively [21]. Nivolumab has received FDA approval 
for the treatment of renal cancer patients who 
have received prior antiangiogenic therapy and 
for the treatment of patients with recurrent or 
metastatic SCCHN with disease progression on 
or after platinum-based therapy.
In May 2016, nivolumab was granted acceler-
ated approval for the treatment of patients with 
classical Hodgkin lymphoma that has relapsed 
or progressed after autologous hematopoietic 
stem cell transplantation and post-transplanta-
tion brentuximab vedotin based on the results 
of a Phase II study. At a median follow-up of 
8.9 months, an ORR of the 66.3% was observed 
among 80 patients treated with a median dura-
tion of response of around 9 months [22]. More 
recently, also pembrolizumab granted FDA 
approval for the treatment of patients with 
refractory classical Hodgkin lymphoma, or those 
who have relapsed after three or more prior lines 
of therapy based on the results of the Phase II 
KEYNOTE-087 trial which showed an ORR 
of 69% with an estimated median response 
 duration of 11.1 months [23].
Predictive biomarkers, more than just 
PD-1/PDL-1
The identification of patients potentially respon-
sive to immunotherapy is one of the challenges 
clinicians are facing at the moment. Biomarkers 
can help clinicians to select patients for immuno-
therapy, avoiding unwanted side effects for 
those patients who are not likely to benefit from 
immunotherapy.
The PD-1/PD-L1/PD-L2 pathway is a key 
immune checkpoint. PD-1 is a transmembrane 
glycoprotein, which acts as a T-cell coinhibitory 
receptor. After cognate antigen detection, PD-1 
10.2217/fon-2017-0085
review Fusi & Dalgleish
future science group
is rapidly upregulated on activated T cells, while 
its expression decreases after antigen clearance. 
Binding of PD-1 by its ligand PD-L1 results in 
inhibition of the activated T cells, switching 
off the T-cell response. PD-L1 is constitutively 
expressed on T- and B-cells as well as on macro-
phages and is also expressed in parenchymal tis-
sues such as endothelial and muscle cells. The 
expression of PD-L1 is greatly increased fol-
lowing stimulation by inflammatory cytokines. 
Given that both PD-1 and PD-L1 are upregu-
lated in tissues during inflammation, and that 
their interaction determines functional inhibi-
tion of lymphocytes, PD-1/PD-L1 plays a key 
role in the local inflammatory response and 
prevention of immune-mediated damage. In 
patients with cancer, because of the constitutive 
antigen exposure, PD-1 is constantly expressed 
on effector T cells and has become a marker of 
unresponsiveness or exhaustion of the T cell. 
PD-L1 can be expressed on cancer cells and on 
cells of the tumor microenvironment. Blocking 
the PD-1/PD-L1 pathway can, therefore, poten-
tially restore the effector function of tumor- 
specific T cells.
The question of whether expression of PD-L1 
correlates with treatment outcomes with anti-
PD-1 and anti-PD-L1 monoclonal antibodies 
has been addressed in most of the pivotal trials.
PD-L1 expression has been generally assessed 
on tumor specimens by immunohistochemis-
try (IHC). A correlation between expression of 
PD-L1 on tumor cells and response to treatment 
was first seen in a Phase I study of nivolumab 
in solid tumors [5]. PD-L1-positive status was 
defined as ≥5% cell membrane staining of any 
intensity, evaluated through IHC using the 
murine antihuman PD-L1 monoclonal anti-
body 5H1. Multiple tumor slides were tested 
for each patient, and a patient was considered 
to have a PD-L1-positive tumor if one biopsy 
sample was positive. Twenty-five patients were 
categorized as PD-L1 positive and 21 as nega-
tive. A treatment response was seen in nine 
PD-L1-positive patients (36%) whereas none of 
the PD-L1 negative had a response. The assess-
ment of PD-L1 positivity was performed in an 
operator-dependent manner. PD-L1 expression 
in subsequent clinical trials of nivolumab has 
been assessed by means of a novel automated 
PD-L1 assay using a rabbit monoclonal antibody 
(clone 28–8).
Using this platform of detection in melanoma 
patients, previously treated with ipilimumab, 
nivolumab showed an ORR of 44% in PD-L1-
positive patients (defined as ≥5% tumor cell 
membrane). However, a significant propor-
tion of patients (20%) defined as being PD-L1 
negative also had a treatment response. Similar 
findings were also observed in the CA209-066 
trial [24] in which nivolumab was compared with 
dacarbazine in patients with BRAF wild-type 
melanoma. Nivolumab was associated with 
a higher ORR than dacarbazine, irrespective 
of PD-L1 status. In PD-L1-positive patients, 
the ORR was 52.7% for nivolumab-treated 
patients and 10.8% for those receiving dacar-
bazine. However, the ORR was also higher 
with nivolumab compared with dacarbazine in 
patients with negative (or indeterminate) PD-L1 
status, even though the response rate was not 
as high and the difference not as marked (33.1 
vs 15.7%). For patients treated with nivolumab, 
the median OS was not reached in either PD-L1 
subgroup. For the patients treated with dacar-
bazine, the median OS was slightly greater in 
the patients with PD-L1-positive melanoma 
(12.4 vs 10.2 months), suggesting an inter action 
between PD-L1 expression and outcome with 
chemotherapy.
In the CheckMate 057 study [12] of nivolumab 
versus docetaxel in patients with nonsquamous 
NSCLC, PD-L1 expression appeared to be a use-
ful predictive factor of response, regardless of 
the cut-off used (1, 5 or 10%). Conversely, in 
the Phase III CheckMate 017 study [11] compar-
ing docetaxel with nivolumab in 272 previously 
treated patients with advanced or metastatic 
squamous NSCLC, the survival benefit and 
improved ORR of nivolumab were independ-
ent of PD-L1 expression level, regardless of the 
cut-off level used to define PD-L1 status (≥1, 5 
or 10%).
The pivotal CheckMate 067 trial compared 
the combination of nivolumab plus ipilimumab 
with nivolumab and ipilimumab monotherapies 
in 945 treatment-naive patients with advanced 
melanoma. Patients were stratified according to 
PD-L1 expression, BRAF mutation and disease 
stage [7]. Subgroup analysis by PD-L1 status 
showed higher ORR for patients treated with the 
combination compared with nivolumab mono-
therapy in both PD-L1-positive patients (72.1 
vs 57.5%) and PD-L1-negative patients (54.8 vs 
41.3%), using a 5% cut-off. However, the median 
PFS for PD-L1-positive patients was 14 months 
for both combination therapy and single agent 
nivolumab compared with 3.9 months in the 
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ipilimumab group. In PD-L1-negative patients, 
median PFS was higher in the combination arm 
compared with nivolumab monotherapy (11.2 
vs 5.3 months). Of note, the fraction of patients 
with positive PD-L1 expression in this study was 
only 21.7%, lower than that observed in other 
studies of anti-PD-1 therapies.
In the clinical trials with pembrolizumab, 
the 22C3 mouse monoclonal antibody has 
been used to assess PD-L1 expression. In the 
pivotal KEYNOTE-006 [24] Pembrolizumab 
(given either every 2 or every 3 weeks) was 
compared with ipilimumab in patients with 
advanced mela noma. PD-L1 status was assessed 
in archival or newly obtained tumor samples by 
means of IHC at a central laboratory before 
randomization and positivity was defined as 
membranous PD-L1 staining in at least 1% of 
tumor cells. Patients receiving pembrolizumab 
showed higher ORR and improved survival. 
Estimated 12-month survival rates were 74.1% 
for pembrolizumab every 2 weeks, 68.4% for 
pembrolizumab every 3 weeks and 58.2% for 
ipilimumab. The pembrolizumab benefit was 
observed across all subgroups and for the two 
regimens, with the exception of 18% of patients 
with PD-L1-negative tumors.
Taken together, these studies suggest that 
while PD-L1 expression has potential as pre-
dictive biomarker, it cannot be currently used 
for patient selection for single agent anti-PD1s 
as a significant number of patients classified as 
PD-L1 negative still benefit from treatment. 
In the complex network of interaction among 
cells of the immune system, absence of expres-
sion of PD-L1 on cancer cells or in the tumor 
microenvironment does not preclude that some 
antitumor activity can be restored by anti-PD1 
antibodies via other immunological pathways.
PD-L1 could help to identify patients who 
can receive greater benefit for the combination 
of ipilimumab and nivolumab over single agent 
nivolumab. However, this should be done with 
caution as the CheckMate 067 study was not 
powered to answer this question, and patients 
with a PD-L1-positive tumor showed a signifi-
cantly higher ORR which may lead to surgery, 
no evidence of (NED) disease in some cases and 
potentially long benefit.
Expression of PD-L1 alone may not be suffi-
cient to identify patients responding to immuno-
therapy and the presence of activated T cells 
within the tumor microenvironment appears to 
be very important. A study of 46 patients with 
metastatic melanoma treated with pembroli-
zumab showed that presence of CD8+ T cells 
prior to treatment located at the invasive tumor 
margin and inside the tumor was associated with 
expression of PD-1 and PD-L1 and predicted 
response to therapy [25]. Similar findings with 
respect of the presence of tumor-infiltrating 
lymphocytes (TILs) were previously observed 
for patients treated with ipilimumab [26]. The 
molecular mechanisms explaining absence of a 
T-cell response have not been fully identified. 
However, recent analyses of human melanoma 
metastases by exome sequencing, gene expres-
sion profiling and IHC have revealed that many 
tumors that lack a T-cell signature showed 
alterations in the Wnt/β-catenin signaling 
pathway [27].
Emerging data have suggested that other bio-
markers based on immunoprofiling and mis-
match repair deficiency and mutational burden 
may useful predictors of treatment response to 
anti-PD1 antibodies.
In an analysis of baseline tumor biopsy, sam-
ples from patients with melanoma enrolled in 
the KEYNOTE-001 study of pembrolizumab, 
both the IFN-α 10 gene and expanded-immune 
28-gene signatures correlated with improved 
ORR and PFS [21]. Similarly, data from a 
Phase I study of patients with RCC treated 
with nivolumab reported that baseline upreg-
ulation of genes known to be upregulated by 
ipilimumab in melanoma, together with other 
immuno related genes, was strongly correlated 
with the outcome [20]. Also, tumors with genetic 
defects in mismatch repair harbor many more 
mutations than tumors of the same type with-
out such repair defects. A strong correlation 
between defects in mismatch repair and response 
to pembrolizumab has been reported in patients 
with colorectal cancer and other solid tumors, 
and it is becoming a major field of interest [28]. 
At the recent The Society for Immunotherapy 
of Cancer (SITC) meeting, Weber et al. pre-
sented a serum test able to identify patients 
with advanced melanoma who are more likely 
to respond to immuno therapy [29]. The poten-
tial responders were associated with complement 
system, acute phase and wound healing func-
tions. The test is under further evaluation in 
a larger cohort of patients. Previous studies in 
cancer vaccine trials have indicated that non-
responders have higher levels of inflammation 
markers (unpublished observations). Chronic 
inflammation is an inhibitor of cell mediated 
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immune responses [30] and using anti-inflam-
matory agents in murine models  significantly 
enhances antitumor responses.
A novel immunogenomic analysis for patients 
with metastatic melanoma receiving single agent 
nivolumab has been presented at the recent 
AACR meeting. In the group of patients receiv-
ing single agent nivolumab, baseline inflamma-
tory gene expression signatures correlated with 
response and response to treatment was also asso-
ciated with increase in CD8 and natural killer 
(NK) cells and decreases in macrophages [31].
The tumor mutational load has been also 
identified as a potential marker. The genetic 
rearrangements of tumor cells can result in the 
generation of tumor-specific peptides with the 
potential to bind major histocompatibility com-
plex molecules, and therefore be recognized by 
the immune system as neoantigens specific for 
the cancer cells. In a retrospective analysis of 
patients with different solid tumors treated with 
single agent checkpoint inhibitors, cancer enti-
ties with high mutational loads showed higher 
response rates to checkpoint blockades com-
pared with cancer with low mutational burden. 
Melanoma, NSCLC and SCCHN are typically 
cancer with a mutational load at least a twofold 
higher compared with cancer entities like sarco-
mas or thyroid cancer [32]. However, also within 
single tumor entities there was a wide range of 
mutational burden.
In NSCLC, smokers have a higher muta-
tional load, and they tend to respond better 
to anti-PD1 antibodies. In a cohort of 16+18 
NSCLC patients, higher somatic nonsynony-
mous mutation burden was associated to a 
molecular smoking signature and with clinical 
efficacy of pembrolizumab [33]. Another study 
showed that patients with metastatic urothelial 
carcinoma and higher mutational load had more 
chances to achieve a complete or partial response 
with the anti-PD-L1 antibody atezolizumab [16]. 
Similarly in patients with metastatic melanoma 
treated with CTLA-4 blockade, long-term clini-
cal benefit was associated to the mutational bur-
den [34]. However, mutational load alone was not 
 sufficient to predict benefit.
Hugo et al. identified a set of transcriptomic 
changes related to innate anti-PD-1 resistance 
(IPRES signature). Pretreatment melanoma 
tumors from patients treated with anti-PD1 anti-
bodies were analyzed for somatic mutanomes 
and transcriptomes. Twenty-one patients were 
classified as responders to treatment and 17 
nonresponders. Twenty-six transcriptomic sig-
natures were coenriched en bloc in 9/13 non-
responding compared with 1/15 responding 
tumors. The signatures were associated with 
increased mesenchymal transition, cell adhesion 
inflammation, wound healing and angiogenesis 
identifying potential genomic determinants 
related to PD-1 blockades response [35]. BRCA 
mutations were associated with better response 
to the treatment.
In a different study, mutations in JAK1/2 have 
been associated with both intrinsic and acquired 
resistance to anti-PD1 antibodies. Patients with 
inactivating mutations of JAK1/2 are likely to 
have an inadequate response to IFN-γ with low 
expression of PD-L1 on the tumor site and lower 
ability of tumor T cells to recognize and kill 
cancer cells [36,37].
Despite all these biomarkers (TILs, PD-L1 
expression, mutational load, etc.) have been sin-
gularly related to response to anti-PD1 block-
ades, none of them represent a reliable predictive 
factor, and none of the markers can be recom-
mended for use in clinical practice. It is in fact 
more likely that all these factors are function-
ally interrelated and a multifactorial biomarker 
approach would potentially provide a stronger 
predictive value. Both PD-1-positive and PD-L1-
negative tumors can respond to treatment and 
PD-L1 is a dynamic marker. PD-L1 is usually 
assessed at baseline similarly to the other bio-
markers, sometimes on archival tissue and we 
do not know how it changes under treatment. 
Longitudinal assessment of potential biomark-
ers would be useful to determine their vari-
ability and to evaluate potential early adaptive 
pathways, which could become predictive fac-
tors as well. The new studies should, therefore, 
include a multifactorial biomarker longitudinal 
assessment with the aim of identifying the bet-
ter marker combination for patient selection. 
Selected clinical trials for theses immunothera-
pies are summarized in Table 1, with a timeline 
of their approval shown in Figure 1.
immunotherapy combinations
In order to enhance and optimize clinical efficacy, 
immunotherapy can be combined with other 
therapeutic modalities, including  chemotherapy, 
radiotherapy and other immunotherapy.
Chemotherapy could act in synergy with 
immunotherapy by promoting the release tumor 
antigens, the depletion of Tregs, by boosting the 
polarization of T-cell immunity toward TH1 
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responses and by increasing the activation of 
NK cells and their number.
Furthermore, the chemotherapy itself can act 
as an immunomodulatory agent. It has been 
shown that common therapeutic agents like 
cyclophosphamide and gemcitabine when given 
at low doses or metronomically can modulate the 
tumor microenvironment favoring the immune 
response [38]. Low doses of MTX can enhance 
antigen processing by dendritic cells (DCs), and 
doxorubicin and paclitaxel are able to upregulate 
HLA and enhance DC functions.
Clinical data about combination strategies 
of immunotherapy with chemotherapy are lim-
ited. The chemotherapy effect of releasing tumor 
antigens is likely, however, to play an important 
role as patients with tumors traditionally chem-
oresponsive, like NSCLC, seem to gain more 
benefit compared with cancer chemoresistant, 
like melanoma. Despite the lack of a direct com-
parison, the outcomes for melanoma patients 
seen with combination ipilimumab plus dac-
arbazine are very similar to the outcomes seen 
with single agent ipilimumab [3]. Results were 
more promising when anti-PD1 antibodies were 
combined with chemotherapy in metastatic gas-
tric cancer and NSCLC and the combination is 
currently under investigation in these two cancer 
entities in large Phase III trials.
Targeted agents can synergize with immuno-
therapy by increasing tumor antigenicity, by 
promoting T-cell migration into the tumor 
and by increasing PD-L1 expression on the 
tumor, as seen for BRAFi. MAPK inhibitors, 
can complement T-cell checkpoint therapies by 
enhancing tumor antigen expression, immuno-
genic tumor cell death and T-cell infiltration 
into tumors. VEGF inhibitors can complement 
T-cell checkpoint therapies by enhancing DC 
maturation and activity as well as T-cell infil-
tration into tumor [39]. A possible disadvantage 
is the inhibition of pathways involved in the 
immune response, but data regarding this issue 
are still controversial. Improved anti tumor activ-
ity has been observed with the combi nation of 
immuno therapy with BRAF and MEK inhibi-
tors in BRAFV600E melanoma, but MEK 
inhibitors also have been shown to have negative 
Table 1. Selected clinic trials of PD-1, PD-L1 and CTLA-4 inhibitors.
Drug Disease Results Ref.
Ipilimumab – Melanoma – Ipi + gp100: 6% ORR; 14% SD; OS 10.0 vs 6.0 mo (gp100 arm) [2]
  – Melanoma – 1 year OS 36.2% 
– 2 year OS 17.9%
[3]
Nivolumab – Melanoma – 1 year OS 73% (nivo) vs 42% (DTIC) [4]
  – Melanoma – ORR 38% (nivo) vs 10% (chemotherapy) [5]
  – Melanoma –2 year OS 64% nivolumab plus ipilimumab; 59% nivolumab S/A and 45% ipilimumab [8]
  – SQ-NSCLC – OS 9.2 mo (nivo) vs 6.0 (docetaxel) [10]
  – nonSQ-NSCLC – OS 12.2 mo (nivo) vs 9.4 (docetaxel) [11]
  – Renal cancer – ORR 25% (nivo) vs 5% (everolimus) 
– Median OS 25.0 mo (nivo) vs 19.6 mo (everolimus) ORR (25 vs 5%)
[15]
  – SCCHN – ORR 13.3% (nivo) vs 5.8% (standard therapy) 
– Median OS 7.5 mo (nivo) vs 5.1 mo (standard therapy)
[16]
  – Urothelial carcinoma – ORR 24% [17]
  – cHL – ORR 66.3%, median duration of response 9.2 mo [22]
Pembrolizumab – Melanoma – ORR 34%, PFS 5.2 mo 2 year OS 50% [7]
  – Melanoma – ORR 33.7% (pembro Q2), 32.9% (pembro Q3) vs 11.9% (ipilimumab). PFS rate at 6 mo 
(pembro Q2) 47.3, 46.4 (pembro Q3) and 26.5% (ipi). OS rate at 12 mo 74.1% (pembro Q2), 
68.4% (pembro Q3) and 58.2% (ipi)
[9]
  – NSCLC – ORR 19.4%, PFS mo 3.7, OS 12 mo [12]
  – NSCLC – Median PFS 10.3 mo (pembro) vs 6.0 mo (chemotherapy group) [13]
  – Urothelial carcinoma – ORR 21% [18]
  – cHL – ORR 69%, median duration of response 11.1 mo [23]
Atezolizumab – NSCLC – Median OS (atezo) 13.8 mo vs 9.6 mo (docetaxel) [15]
  – Urothelial carcinoma – ORR 16% [16]
Durvalumab – Urothelial carcinoma – ORR 31% [19]
cHL: Classical Hodgkin lymphoma; DTIC: Dacarbazine; mo: Months; NSCLC: Non-small-cell lung cancer; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free 
survival; S/A: Single agent; SCCHN: Squamous cell carcinoma of the head and neck; SD: Standard deviation.
10.2217/fon-2017-0085
Fi
gu
re
 1
. U
S 
FD
A
 ti
m
e 
lin
e 
ap
pr
ov
al
 o
f i
m
m
un
e 
ch
ec
kp
oi
nt
 b
lo
ck
ad
es
 fo
r c
an
ce
r t
re
at
m
en
t. 
 
H
N
SC
C:
 H
ea
d 
an
d 
ne
ck
 s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a;
 N
SC
LC
: N
on
-s
m
al
l-c
el
l l
un
g 
ca
nc
er
.
A
te
zo
liz
um
ab
 a
pp
ro
ve
d 
fo
r
ur
ot
he
lia
l c
ar
ci
no
m
a
P
em
br
ol
iz
um
ab
 a
pp
ro
ve
d 
fo
r 
N
S
C
LC
Ip
ili
m
um
ab
 a
pp
ro
ve
d 
fo
r
m
et
as
ta
tic
 m
el
an
om
a
N
iv
ol
um
ab
 a
pp
ro
ve
d 
fo
r 
N
S
C
LC
N
iv
ol
um
ab
 a
pp
ro
ve
d 
fo
r 
m
et
as
ta
tic
re
na
l c
el
l c
ar
ci
no
m
a
N
iv
ol
um
ab
 a
nd
 p
em
br
ol
iz
um
ab
ap
pr
ov
ed
 fo
r 
H
N
S
C
C
A
te
zo
liz
um
ab
 a
pp
ro
ve
d 
fo
r
ad
va
nc
ed
 b
la
dd
er
 c
an
ce
r
P
em
br
ol
iz
um
ab
 a
pp
ro
ve
d 
fo
r 
cH
L
20
11
20
15
20
16
20
17
N
iv
ol
um
ab
 a
nd
 p
em
br
ol
iz
um
ab
ap
pr
ov
ed
 fo
r 
m
et
as
ta
tic
 m
el
an
om
a
C
om
bi
na
tio
n 
of
 n
iv
ol
um
ab
 a
nd
ip
ili
m
um
ab
 a
pp
ro
ve
d 
fo
r 
m
et
as
ta
tic
m
el
an
om
a
A
te
zo
liz
um
ab
 a
pp
ro
ve
d 
fo
r 
N
S
C
LC
N
iv
ol
um
ab
 a
pp
ro
ve
d 
cH
L
A
ve
lu
m
ab
 a
pp
ro
ve
d 
fo
r
m
et
as
ta
tic
 M
er
ke
l c
ar
ci
no
m
a
N
iv
ol
um
ab
 a
pp
ro
ve
d 
fo
r 
m
et
as
ta
tic
ur
ot
he
lia
l c
ar
ci
no
m
a
review Fusi & Dalgleish
future science group
effects on naive T-cell proliferation, viability and 
IFN-γ secretion [39]. However, in clinical prac-
tice a major problem of such a combination is 
the tolerability. The Phase I study combining 
ipilimumab and vemurafenib had to be stopped 
due to the high liver toxicity despite a strong 
rationale of using this combination. The BRAFi 
vemurafenib has shown in fact to enhance T-cell 
recognition of melanoma [40] improves anti tumor 
activity of adoptive cell immunotherapy [41], and 
it increases tumor infiltration by T cells [42]. 
Further combinations have been considered and 
some of them are currently under investigation 
in Phase III trials with a more acceptable toxic-
ity profile. The combination of dabrafenib with 
ipilimumab, for instance, appeared to be toler-
able and has not been associated with significant 
hepatotoxicity in melanoma. On the contrary, 
the combination of dabrafenib, trametinib with 
ipilimumab was stopped early after two out of 
seven patients developed colon perforation soon 
after initiating ipilimumab therapy.
Immunotherapy can be combined with radio-
therapy. Radiotherapy can promote release of 
tumor antigen, inflammation and migration 
of cells of the immune system to the irradiated 
tumor (cold to hot tumor), can increase the 
number of neoantigens making the tumor more 
recognizable by the immune system and can 
promote the activation of immunogenic death 
pathways. But the most interesting effect seen 
with such a combination is the so-called absco-
pal effect (out-of-target tumor response). The 
best example of this is the study of Kolstad et al., 
which showed that combining radiotherapy with 
intranodal injection of low-dose rituximab, 
immature DCs and granulocyte-macrophage 
colonystimulating factor (GM-CSF) in patients 
with disseminated follicular lymphoma can 
induce systemic CD8 T-cell immunity and 
tumor regression [43].
The combination of two different immuno-
therapeutics has many potential advantages. 
Different agents can in fact boost the immune 
response by acting on different levels and on 
different stages of the immune response. By 
acting predominantly on early or late stages 
of the immune response we can modulate the 
specificity of the response, being less specific 
or more specific, respectively. By acting on the 
afferent phase of the immune response we can 
increase the magnitude of T-cell response and 
their avidity. By predominantly acting on the 
efferent phase we would be able to increase the 
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trafficking and to modulate tolerance mecha-
nism. Anti-CTLA4 and anti-PD1 therapies are 
synergistic when combined together because of 
their complementary effects on T-cell priming 
in the lymph nodes and T-cell activation and 
killing in the tumors. We have previously dis-
cussed the findings of the CheckMate 067 study, 
which evaluated the combination ipilimumab 
and nivolumab against single agent treatment, 
but we did not mention the toxicity profile. This 
is one of the challenges for the clinicians as the 
combination showed poor tolerability as more 
than 50% of the patients experienced grade 3 
and 4 toxicities. The most of these toxicities were 
immune related and some of them are chronic. 
New combination strategies are warranted in 
order to reduce toxicity. The CheckMate study 
067 is a Phase II study, which evaluated the com-
bination of ipilimumab and nivolumab given 
sequentially rather than concurrently with a 
planned switch. The treatment given sequen-
tially did not show a better toxicity profile. 
Furthermore, the cohort of patients receiving 
ipilimumab first, followed by nivolumab, did 
unexpectedly significantly worse in terms of 
ORR and progression rate compared with the 
cohort of patients receiving nivolumab first.
The combination of these agents with TILs or 
modified T cells can help to address this issue as 
driving a more specific tumor immune response 
might improve the toxicity profile, avoiding the 
immune-related adverse events we see with the 
checkpoint blockades. Preliminary results are 
encouraging, but it is still too early to see such a 
kind of combination in late phase trials.
Novel immunotherapeutics & future 
perspective
It is important to realize just how many mol-
ecules can be included under the title of 
‘Checkpoint.’ CTLA-4 and PD-1 are exam-
ples of inhibitors that include many others, 
including TIM-3, BTLA, VISTA and LAG-3. 
Checkpoints can also be stimulated with ago-
nist antibodies such as CD28, 0X40, GITR, 
CD137, CD27 and HVEM. Among these, 
the novel anti-CD137, urelumab, has already 
entered Phase II trials. Urelumab demonstrated 
antitumor activity through the enhancement of 
T cells and NK activities. In a Phase I–II com-
bination study with the nivolumab, 33 out of 71 
patients had a reduction in the tumor burden 
to RECIST criteria. Combinations of an ago-
nist and antagonist are attractive in theory but 
need to be tempered by the potential side effects 
exemplified by the Northwick Park Phase I dis-
aster with a CD28-based antibody. Nevertheless, 
CD27 (varlilumab) is being developed with an 
anti-PD-L1 antibody (atezolizumab) by Celldex 
(NJ, USA). Combinations currently in devel-
opment, interestingly, include many candidates 
that have failed to be effective in previous stud-
ies, such as tumor antigen vaccines, as well as 
agents with marked activity in a small percent-
age of patients, for example, intratumoral agents 
such as talimogene laherparepvec (T-VEC). 
Idera Pharmaceuticals (MA, USA) are using 
an intratumoral TLR9 agonist to modulate the 
tumor microenvironment to enhance antitumor 
immunity (together with ipilimumab). Other 
approaches include combining with anti-KIR 
(lirilumab) to target NK cells with both ipili-
mumab and nivolumab. To date, all checkpoints 
have been intravenous antibodies, but this may 
change as Curis (MA, USA) has announced that 
they have an oral checkpoint inhibitor that is 
very encouraging in preclinical trials (CA170).
Beyond the checkpoints, many high-tech 
approaches are being pursued, such as antitumor 
vaccination, oncolytic strategies, bispecific anti-
bodies, CAR T cells, etc. However, we may have 
overlooked very basic low tech approaches in the 
rush to develop more and more sophisticated 
agents. These include simple immune modula-
tors/anti-inflammatories, such as the IMiDs, 
IMM-101, many drugs in low doses, such as 
cyclophosphamide and gemcitabine and the use 
of basic TLR agonists and already developed 
cytokines. The most impressive studies have 
used lenalidomide and pomalidomide, which, in 
addition to inhibiting COX-2, are very costimu-
latory [44]. It is a logical step to prime with these 
agents in any immunotherapy strategy.
This may or may not be linked to the role of 
activated mononuclear phagocytes/macrophages 
in the outcome of checkpoint therapy [45] where 
it has been shown that the induction of the 
CD103+ marker on DCs is an absolute required 
for PD-1-based therapy to be effective in a 
murine model.
This is of interest as a review of many dif-
ferent vaccine studies over the last two decades 
highlighted the excellent long-term outcome of 
patients given a heat-killed mycobacterium vac-
cine preparation (also known as SRL-172) with 
stage IV melanoma patients achieving similar 
5- and 8-year survivals to that reported using 
ipilimumab. Unfortunately, by the time this was 
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evident SR Pharma (Halifax, UK) had dropped 
the project to pursue more high-tech approaches. 
Further research suggested that a closely related 
agent (Mycobacterium obuense) was as effective 
and much easier to produce to good manufactur-
ing practice and Immodulon (London, UK) have 
now produced this as IMM-101, which has been 
shown to be active alone in melanoma [46] and 
with gemcitabine versus gemcitabine alone in a 
randomized study in advanced pancreatic cancer 
patients [47]. This agent has the advantages of 
being a TLR-2 and 4 agonist, having multiple 
antigens, many shared with tumors, as well as 
the ability to activate both innate (NK and γδ 
T cells) and the cell mediated (Th-1) response. 
In addition, it can activate macrophages. More 
importantly, it has no added side effects, being 
a very small intradermal (0.1 ml) injection with 
no negative systemic effects at all.
This agent has already been shown to increase 
the effects of low dose IL-2, gemcitabine, zole-
dronic acid and carboplatin-based chemother-
apy, as well as radiotherapy. Early anecdotal data 
(reported at SITC 2016) suggest that patients 
pretreated with IMM-101, who progress, have 
had exceptional responses to ipilimumab and 
pembrolizumab and a combined study has now 
commenced to explore this potential synergy.
A combinatorial immunotherapeutic strat-
egy of combining CAR T cells with checkpoint 
blockade is a promising treatment approach 
for solid tumors. In a murine model of meso-
thelioma, Cherkassky et al. [48] showed that high 
doses of CD28- and 4–1BB-based CAR T cells 
were able to eradicate the tumor. 4–1BB CAR T 
cells retained their cytotoxic and cytokine secre-
tion functions longer than CD28 CAR T cells, 
and their prolonged function correlated with 
improved survival. Only when a PD-1-blocking 
antibody was added, the effector function of 
exhausted CD28 CAR T cells was restored sug-
gesting that PD1 blockade may overcome CAR 
T-cell exhaustion often observed in solid tumors.
Oncolytic viruses are another very promising 
strategy and a wide variety of oncolytic viruses are 
currently under clinical development worldwide. 
They consist of genetically engineered or naturally 
occurring viruses that selectively replicate in and 
kill cancer cells. In a Phase III clinical trial, T-VEC 
showed to improve the outcome of patients with 
metastatic melanoma. T-VEC is based on herpes 
simplex virus type 1 and has been modified to 
include a gene that codes for GM-CSF. In the 
study for T-VEC showed an ORR of 26.4 versus 
5.7% of the control arm consisting of subcutane-
ous administration of GM-CSF with median OS 
of 23.3 months with T-VEC versus 18.9 months 
with GM-CSF [49]. Oncolytic viruses can be com-
bined with immune checkpoint blockades as cur-
rently under investigation for T-VEC or with non-
immunotherapeutical agents. Lawson et al. [50] 
have evaluated the combination of sunitinib with 
a reovirus in a murine model of renal cancer and 
observed that the combination of sunitinib with 
reovirus was able to improve survival and to pro-
mote the development of protective immunity 
upon tumor rechallenge compared with sunitinib 
 single agent or reovirus alone.
Bispecific antibodies are capable of binding 
two targets simultaneously. They are produced as 
recombinant proteins with two antigen-binding 
regions with or without Fc. Bispecific antibod-
ies can be used to block two different sig naling 
pathways simultaneously, to dual target different 
disease mediators or to simply recruit cells of the 
immune system to the tumor site. Catumaxomab 
is an anti-EpCAM-anti-CD3 antibody approved 
in the EU for the treatment of recurrent malignant 
ascites [51], and blinatumomab is an anti-CD19 
and anti-CD3 antibody approved in the USA for 
the treatment of Philadelphia chromosome-neg-
ative relapsed or refractory acute lymphoblastic 
leukemia [52]. Bispecific antibodies might have a 
role in combination with checkpoint blockades. 
Presence of TILs and tumor-specific T cells cor-
relate with response to anti-PD1 antibodies. 
Recruitment of T cells at tumor level, retarget-
ing of T cells to tumor and activation of T cells 
may, therefore, increase the activity of immune 
checkpoint blockades and switch nonresponders 
into responders.
Another very interesting approach consist 
of the so-called nanovaccines. In a preclinical 
model of Kim et al. showed that nanoparticles 
encapsulating a imidazoquinoline derivative 
that activates both toll-like receptor 7 and 8 
used in combination with a model antigen were 
able to improve DC activation in the lymph 
node, increase the activation of T cells and of 
 frequency of antigen-specific T cells [53].
One last point is whether the fixation on 
combinations can be overdone when it may be 
more important to get the sequence right and 
this is not always predictable on known scien-
tific data, for example, the poor results with 
nivolumab given after ipilimumab, compared 
with the other way round was the complete 
opposite of what was predicted, highlighting 
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executive summary
 ●  In 2016, cancer immunotherapy has been named Advance of the Year by the American Society of Clinical Oncology.
Checkpoint blockades: state of art
 ●  The CTLA-4 antibody ipilimumab and the anti-PD1 antibodies pembrolizumab and nivolumab have granted approval 
for the treatment of metastatic melanoma, and they are the new standard of care for this disease. Nivolumab and 
pebmbrolizumab received approval for the treatment of patients with non-small-cell lung cancer whose disease has 
progressed after at least one line of treatment. Atezolizumab was the first ever anti-PD-L1 antibody approved by 
US FDA. It is indicated for patients with metastatic non-small-cell lung cancer whose disease progressed during or 
following platinum-containing chemotherapy. Significant efficacy and prolongation of progression-free survival and 
overall survival has been observed for nivolumab also in patients with metastatic renal cancer and advanced head 
and neck cancer. Nivolumab has received approval for the treatment of renal cancer patients who have received 
prior antiangiogenic therapy and for the treatment of patients with recurrent or metastatic squamous cell carcinoma 
of the head and neck with disease progression on or after platinum-based therapy. Pembrolizumab and nivolumab 
are approved treatment for refractory or recurrent classical Hodgkin lymphoma based on Phase II studies results. 
Continued approval for this indication will depend on the outcome of ongoing randomized Phase III studies.
Predictive biomarkers, more than just PD-1/PDL-1
 ●  Studies suggested that while PD-L1 expression has potential as a predictive biomarker, it cannot be currently used for 
patient selection for single agent anti-PD1s as a significant number of patients classified as PD-L1 negative still benefit 
from treatment.
 ●  Emerging data have suggested that biomarkers based on immunoprofiling and mismatch repair deficiency may be 
more useful predictors of treatment response than PD-L1.
 ●  A multifactorial biomarker approach can potentially provide a stronger predictive value.
immunotherapy combinations
 ●  In order to enhance and optimize clinical efficacy, immunotherapy can be combined with other therapeutic modalities 
including chemotherapy, radiotherapy and other immunotherapy.
 ●  Chemotherapy and targeted agents could act in synergy with immunotherapy by promoting the release tumor 
antigens, the depletion of Tregs, by boosting the polarization of T-cell immunity toward TH1 responses and by 
increasing the activation of natural killer cells and their number. Furthermore, BRAFi can potentially increase PD-L1 
expression.
 ●  Radiotherapy can synergize with immunotherapy by increasing the number of neoantigens making the tumor more 
recognizable by the immune system and by promoting the activation of immunogenic death pathways.
 ●  Combination of checkpoint inhibitors is a promising strategy; however, it is limited by the increased toxicity.
Novel immunotherapeutics & future perspective
 ●  New checkpoint inhibitors include anti- TIM-3, BTLA, VISTA and LAG-3. Checkpoints can also be stimulated with 
agonist antibodies such as CD28, 0X40, GITR, CD137, CD27 and HVEM.
 ●  Beyond the checkpoints, many high-tech approaches are being pursued, such as oncolytic intratumoral strategies 
(talimogene laherparepvec), bispecific antibodies, CAR T cells, etc., but except for talimogene laherparepvec none has 
entered clinical practice so far.
Conclusion
 ●  Different approaches may have a different potential in gaining benefit for different patients. Treatment with 
checkpoint blockades should be optimized in order to increase benefit minimizing the toxicity.
 ●  A potential strategy is to establish a baseline ‘immunogenicity score’ using a panel of biomarkers which includes 
microenvironment-related biomarkers and select the most appropriate strategy (more aggressive versus less 
aggressive) based on this score.
 ●  This would require a deeper understanding of the biology of the tumor in the context of immunotherapy, including 
the understating of the mechanisms of acquired resistance to immunotherapy.
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the importance of performing trials with several 
permutations [54].
Conclusion
Most healthcare systems are cracking at the 
seams with the unexpected cost of new cancer 
agents, especially when they often give only an 
extra survival of a few months in many cases. 
Combinations of such expensive drugs, which 
can cost up to £100K a year is seen as a step too 
far by even those involved in their development. 
This means that there must be a place for back 
to basic, simpler approaches, which might just 
prime the tumor environment to respond better 
to checkpoint inhibitors.
Previous immunotherapy has been focused 
on cytokines (interferons and interleukins), 
TLR agonists, such as TLR7 and TLR9, and 
vaccination-based strategies. Cytokines, such 
as IL-2 expand activated T cells even at non-
toxic low levels and should not be overlooked in 
 optimizing checkpoint inhibitor strategies.
Different approaches may have a different 
potential in gaining benefit for different patients. 
We would need a strategy for personalized can-
cer immunotherapy to increase the therapeutic 
index. A potential strategy is to establish a base-
line ‘immunogenicity score’ using a panel of bio-
markers that include microenvironment-related 
biomarkers [55]. Tumors with high score and a 
responsive microenvironment may be treated 
with monotherapy targeting T-cell response. 
Tumors with a low score would need a more 
aggressive approach targeting both T cells and 
microenvironment.
However, this would require a deeper under-
standing of the biology of the tumor in the con-
text of immunotherapy, including the understat-
ing of the mechanisms of acquired resistance to 
immunotherapy. A new challenge that we are 
facing now as we have started seeing patients 
becoming resistant to treatment even after a long 
period of benefit.
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